MedTrace Logo

Cardiorenal Effecs of Losartan in Kidney Transplant Recipients

NCT05243446 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 740

Last updated 2022-02-17

No results posted yet for this study

Summary

The influence of Losartan to cardiovascular and renal outcomes in patients after renal transplatation.

Conditions

  • Renal Transplant Failure
  • Cardiovascular Complication

Interventions

DRUG

Losartan

losartan treatment

Sponsors & Collaborators

  • Medical University of Warsaw

    collaborator OTHER

  • Pomeranian Medical University Szczecin

    collaborator OTHER

  • Jagiellonian University

    collaborator OTHER

  • Medical University of Bialystok

    collaborator OTHER

  • Nicolaus Copernicus University

    collaborator OTHER

  • Medical University of Silesia

    collaborator OTHER

  • Poznan Regional Hospital

    collaborator UNKNOWN

  • Wroclaw Medical University

    collaborator OTHER

  • Medical University of Gdansk

    lead OTHER

Principal Investigators

  • Leszek Tylicki, professor · Medical University of Gdansk

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2022-12-31
Completion
2023-12-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05243446 on ClinicalTrials.gov